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Abstract
Introduction: Protein C, because of its central role in hemostasis, plays an integral role in the host response to
infection. Protein C depletion, resulting from increased consumption, degradation, and/or decreased synthesis, is
characteristic of sepsis and has been shown to predict morbidity and mortality. The objective of this study was to
determine whether early directional changes in protein C levels correlate with outcome.
Methods: Patients in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis
(PROWESS) clinical trial were assessed and categorized by baseline protein C (n = 1574). Deficiency was categorized
as: severe deficiency, protein C levels ≤ 40% of normal protein C activity (n = 615, 39% of patients); deficient,
protein C levels 41–80% of normal protein C activity (n = 764, 48.5% of patients); and normal, >80% of normal
protein C activity (n = 195, 12.4% of patients). Logistic regression analysis of 28-day mortality for placebo patients
was used to investigate whether baseline and day 1 protein C levels were independent risk factors for mortality.
The impact of treatment with drotrecogin alfa (activated) (DrotAA) was also assessed.
Results: Protein C levels at baseline and day 1 were independent risk factors in placebo patients. If baseline protein C
levels of severely deficient placebo patients remained ≤ 40% at day 1 their odds of death increased (odds ratio = 2.75,
P < 0.0001), while if levels improved to >40% by day 1 their risk of death decreased (odds ratio = 0.43, P = 0.03). If
baseline protein C levels of placebo patients were >40% but decreased by ≥ 10% on day 1, their risk of death increased
(odds ratio = 1.87, P = 0.02). DrotAA treatment improved protein C levels by day 1 compared with placebo (P = 0.008)
and reduced the risk of death in severely deficient (≤ 40%) patients at baseline. Treatment also decreased the number
of severely protein C deficient (= 40%) patients and decreased the number of deficient (41–80%) patients and normal
(>80%) patients who had a ≥ 10% decrease in protein C levels by day 1.
Conclusion: Baseline protein C levels were an independent predictor of sepsis outcome. Day 1 changes in protein
C, regardless of baseline levels, were also predictive of outcome. The association of DrotAA treatment, increased
protein C levels, and improved survival may partially explain the mechanism of action.
Introduction
The protein C pathway, because of its central role in
hemostasis, plays an integral role in the host response to
infection. Activated protein C inactivates coagulation fac-
tors, enhances fibrinolysis, and at high concentrations
reduces the release of inflammatory cytokines [1-6]. Due
to increased consumption, degradation, and/or decreased
synthesis, protein C deficiency is characteristic of severe
sepsis – with the onset of protein C deficiency probably
occurring before clinical diagnosis of organ dysfunction
[7-9]. Numerous studies have demonstrated that
decreased circulating levels of protein C in septic patients
are associated with increased morbidity and mortality
[7-11]. The extent of protein C deficiency, assessed at the
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time of diagnosis, correlates with increased morbidity
and mortality, but only as a threshold [12]; that is, only
severe protein C deficiency (protein C levels ≤ 40% of
normal protein C activity) correlates with decreased sur-
vival. Continued protein C deficiency or the development
of protein C deficiency within approximately one day of
diagnosis, however, has been correlated with early death
[12].
Drotrecogin alfa (activated) (DrotAA) has been shown to
improve survival in patients with severe sepsis [13] and to
increase protein C levels [14]. This effect appears to be
unique to protein C, as similar findings were not observed
with protein S and antithrombin III. The treatment effect
appeared independent of baseline protein C measurements
[15], although a priori it was hypothesized that protein-C-
deficient patients would derive the most benefit from
treatment.
We hypothesized that early (baseline to day 1) direc-
tional changes in protein C (naturally occurring or from
DrotAA treatment) would correlate with outcome. Since
lower protein C levels appear to correlate with worse out-
comes, we explored whether the observed change from
baseline in the first day (either an increase or decrease)
would contribute meaningful additional information to
baseline levels of protein C, with respect to predicting out-
come. In addition, we explored whether treatment with
DrotAA would reduce the number of patients with day 1
decreases in protein C levels or increase the number of
patients that improved from severe protein C deficiency.
Materials and methods
Patients
The Recombinant Human Activated Protein C Worldwide
Evaluation in Severe Sepsis (PROWESS) trial was con-
ducted in accordance with ethical principles that have
their origin in the Declaration of Helsinki and are consis-
tent with good clinical practices and applicable laws and
regulations. The trial design, patient disposition, inclusion/
exclusion criteria, and results of the pivotal PROWESS
clinical trial have been described in detail previously [13].
Briefly, PROWESS was a multicountry (164 sites in 11
countries), randomized, placebo-controlled clinical trial of
DrotAA (Xigris®; Eli Lilly and Company, Indianapolis, IN,
USA) in adult patients with severe sepsis. All investigative
sites obtained approval for the study from their institu-
tional review boards. Written informed consent was
obtained from all patients or their legal representatives.
Although protein C activity levels were measured in the
PROWESS trial, patients with missing baseline protein C
activity values were excluded from these analyses.
Samples
In the PROWESS trial, plasma samples were obtained at
baseline and daily through study day 7. A central laboratory
(Covance Central Laboratory Services, Indianapolis, IN,
USA) performed all assays. The protein C activity assay
was performed on a STA® coagulation analyzer using the
STA®-Staclot® Protein C kit (Diagnostica Stago, Asnieres-
Sur-Seine, France), which has a coefficient of variation of
7.5%. Protein S measurements were performed on the
STA® coagulation analyzer using the STA®-Staclot®
Protein S kit (Diagnostica Stago). The antithrombin III
activity was quantitated using a chromogenic activity assay
(Stachrome ATIII; Diagnostica Stago). IL-6 antigen levels
were measured by enzyme immunoassay (Quantikine
Human IL-6 HS kit; R&D Systems, Minneapolis, MN,
USA).
Statistical methods
The relationship between baseline protein C levels and
clinical variables was assessed with Spearman rank correla-
tion when both variables were continuous, and was
assessed with the Wilcoxon rank-sum test (for groups
with two levels, for example comorbidities) when continu-
ous protein C levels were compared between two classes.
Protein C classes were defined prospectively [13,15]
into normal (>80% of normal protein C activity), deficient
(41–80% of normal protein C activity), and severely defi-
cient (≤ 40% of normal protein C activity). The protein C
status was evaluated to determine whether it was a signif-
icant risk factor for mortality among PROWESS placebo
patients. Multivariable logistic regression was used to
adjust for six risk factors (Acute Physiology and Chronic
Health Evaluation (APACHE) II score, age, baseline IL-6
level, presence of comorbidities, presence of any depen-
dencies as determined by ability to conduct activities of
daily living [16], and urosepsis) previously found to be
significant predictors of outcome in analyses of data from
PROWESS placebo patients [15]. Baseline protein C
classes were initially included. Variables assessing protein
C change from baseline were subsequently included in
stepwise logistic regression. In some cases the moderately
deficient protein C and normal protein C classes were
combined for analysis of mortality by baseline protein C
activity levels, after it was determined that there was no
increased risk in the odds of death (odds ratio = 0.89, P =
0.07, comparing 41–80% of normal protein C activity
with >80% of normal protein C activity; see Table 2),
over the time frame analyzed.
For patients with both baseline and day 1 protein C
measurements, treatment differences of antithrombin,
IL-6, and protein S levels at baseline and day 1, and
their changes, were compared with Wilcoxon rank-
sum tests. Survival patterns were illustrated with
Kaplan-Meier estimates and were compared using log-
rank tests. Statistical analyses were performed using
SAS version 8.02 software (SAS Institute Inc., Cary,
NC, USA).
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Results
The PROWESS trial enrolled 1690 patients, of which 850
received DrotAA and 840 received placebo. Baseline pro-
tein C measurements were obtained for 1574 patients (799
receiving DrotAA and 775 receiving placebo). Patients
who had missing baseline protein C values did not signifi-
cantly differ from the overall population in baseline char-
acteristics, disease severity measures, or outcomes (data
not shown). Values ranged from 5% to 200% of normal,
with an average of 50.6 ± 26.7% (mean ± standard devia-
tion). Using prospectively defined criteria, patients were
classified as either severely deficient (≤ 40% activity, n =
615, 39.1% of patients), deficient (41–80% activity, n =
764, 48.5% of patients), or normal (>80% activity, n = 195,
12.4% of patients). It should be emphasized that the levels
of protein C reported relate to levels of endogenous inacti-
vated protein C. In addition, the reported protein C values
do not reflect intravenously administered DrotAA.
Relationship between baseline protein C class, clinical
and demographic characteristics, and 28-day mortality
Table 1 presents seven baseline characteristics of PRO-
WESS patients as they relate to baseline protein C class
and treatment group. Six of the baseline characteristics
(APACHE II score, age, log IL-6, presence of comorbid-
ities, presence of dependencies, and urosepsis) have pre-
viously been shown to predict outcome among PROWESS
placebo patients [15] and were specifically chosen to pre-
sent for that reason (see Table 2). Significant correlations
were observed across baseline protein C classes for the
APACHE II score and IL-6 (P < 0.0001 for both). Comor-
bidities, dependencies, and septic shock also had a signifi-
cant association with baseline protein C levels (all P ≤
0.007). The 28-day mortality among the PROWESS pla-
cebo patients was significantly higher in the severely defi-
cient (≤ 40% activity) protein C group than in the deficient
(41–80% activity, P < 0.0001) and normal (>80% activity,
Table 1 Baseline characteristics and 28-day mortality of PROWESS patients by baseline protein C level and treatment
group
Parameter Baseline protein C ≤ 40% of normal Baseline protein C 41–80% of normal Baseline protein C >80% of normal
Placebo (n = 285) DrotAA (n = 330) Placebo (n = 385) DrotAA (n = 379) Placebo (n = 105) DrotAA (n = 90)
APACHE II score* 26.1 ± 8.1 25.6 ± 7.7 24.3 ± 7.8 23.9 ± 7.5 23.9 ± 7.3 23.8 ± 6.7
Age (years) 61.4 ± 16.9 60.9 ± 17.1 60.0 ± 16.7 59.9 ± 17.8 61.9 ± 14.6 61.4 ± 16.4
Log IL-6* 7.4 ± 2.1 7.5 ± 2.2 6.1 ± 2.0 6.2 ± 2.0 4.7 ± 1.8 4.7 ± 1.7
Urosepsis (%) 9.8 10.3 12.2 8.7 3.8 14.4
Comorbiditesa (%)** 16.5 15.5 20.0 19.8 35.2 34.4
Dependenciesb (%)** 25.3 21.8 29.6 29.3 38.1 33.3
Septic shock (%)** 76.8 80.6 72.2 66.0 59.0 55.6
28-day mortality (%) 41.8 27.6 24.9 24.0 26.7 15.6
DrotAA, drotrecogin alfa (activated). Patients were prospectively categorized on the basis of their baseline protein C activity levels (normal, >80%; deficient, 41–
80% of normal; and severely deficient, ≤ 40% of normal). aAny chronic health points from the (APACHE) II classification system. bPatient considered dependent if
they were dependent in one or more activities on the Activities of Daily Living scale [16]. *Significantly different between protein C classes (P < 0.05) using
Spearman rank-correlation with baseline protein C levels. **Significant (P < 0.05) association with baseline protein C levels using Wilcoxon rank-sum tests
comparing the “yes” versus “no” classifications
Table 2 Protein C and additional measures as risk factors in PROWESS placebo patients










APACHE II scoreb 1.31 1.16–1.48 <0.0001 1.33 1.17–1.51 <0.0001
Agec 1.17 1.10–1.24 <0.0001 1.17 1.10–1.24 <0.0001
Log IL-6d 1.48 1.22–1.80 <0.0001 1.30 1.06–1.60 0.010
Comorbidity 2.00 1.32–3.03 0.001 1.80 1.17–2.78 0.008
Dependenciese 1.70 1.17–2.46 0.006 1.81 1.23–2.68 0.003
Urosepsis 0.47 0.25–0.87 0.020 0.42 0.22–0.79 0.008
Baseline protein C ≤ 40% 1.75 1.21–2.53 0.003 2.74 1.75–4.30 <0.0001
Baseline protein C ≤ 40% and day 1 protein C >40% - - - 0.43 0.20–0.93 0.030
Baseline protein C >40% and day 1 protein C 10%
decrease
- - - 1.87 1.12–3.11 0.020
APACHE, Acute Physiology and Chronic Health Evaluation. All patients with baseline protein C values from the PROWESS trial (n = 1574) were included in
analyses. Risk factors used were previously found to be significant predictors of outcome in analyses of data from PROWESS [15]. aBased on multivariable logistic
regression; values >1 indicate increased risk, values <1 indicate lower risk. bPer 5-point increase in baseline score. cPer 5-year increase in age. dPer 10 times
increase in baseline IL-6. ePatient was considered dependent if they were dependent in one or more activities on the Activities of Daily Living scale [16].
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P = 0.006) protein C groups. The deficient and normal
groups, however, did not differ significantly from each
other (P = 0.71).
Baseline and day 1 changes in protein C levels predict
mortality in PROWESS placebo patients
To determine whether low or decreasing protein C places
patients at a high risk of mortality, analyses adjusting for
six previously defined significant risk factors (APACHE II
score, age, log IL-6, presence of comorbidities, presence of
dependencies, and urosepsis) [15] were performed on data
from PROWESS placebo patients (Table 2). Baseline severe
protein C deficiency (≤ 40% activity) was associated with a
significantly higher risk of death (adjusted odds ratio =
1.75, P = 0.003) than those patients without severe defi-
ciency (baseline protein C level 41–80% and >80% activity).
Changes in protein C activity level in the first day also
significantly predicted the risk of death (Table 2). If pla-
cebo patients were severely deficient at baseline and
remained severely deficient on day 1, their odds of death
were 2.74 times higher than other placebo patients (P <
0.0001). Placebo patients with deficient (41–80%) and nor-
mal (>80%) protein C activity levels at baseline (for exam-
ple, baseline protein C >40% in Table 2) who had a ≥ 10%
decrease in protein C levels on day 1 also had a signifi-
cantly increased risk of death (odds ratio = 1.87, P = 0.02),
compared with patients who did not have a decrease of
this magnitude. If placebo patients were severely deficient
(≤ 40%) at baseline but improved to >40% activity by day
1, their risk of death was significantly reduced compared
with patients whose protein C activity levels remained ≤
40% (odds ratio = 0.43, P = 0.03). Other variables asso-
ciated with change did not enter the model. For instance,
no significant increased risk was observed for day 1 pro-
tein C decreases in the severely deficient subgroup (≤ 40%
activity). In contrast, no significant decreased risks were
observed for day 1 protein C increases in the deficient
(41–80% activity) and normal (>80% activity) subgroups
(for example, baseline levels >40% activity).
To illustrate the significance observed in day 1 protein C
changes, the PROWESS placebo mortality rates, based on
baseline levels and first day protein C changes, are pre-
sented in Figure 1. Of the severely deficient placebo
patients (Figure 1, left-hand bar graphs), 7.4% did not sur-
vive to day 1 for a second protein C measure (area above
the dotted line). After removing patients who died before
the day 1 protein C measurement was taken (dotted line),
the mortality of severely deficient patients at baseline
(34.9%) increased to 40.7% if their protein C levels
remained ≤ 40% and decreased to 24.5% if their levels rose
above 40%.
In the middle set of bar graphs in Figure 1, 1.0% of mod-
erately deficient placebo patients died before a second
measure could be taken (area above dotted line). After
removing patients who died before a day 1 protein C mea-
surement was taken (dotted line), the mortality of deficient
patients at baseline (24.0%) increased to 31.1% if there was
≥ 10% decrease in their protein C levels and decreased to
21.0% if no decrease ≥ 10% occurred.
Finally, in the right-hand set of bar graphs in Figure 1,
1.0% of placebo patients with normal protein C levels died
before a second measure could be taken (area above
dotted line). After removing patients who died before a
day 1 protein C measurement was taken (dotted line), the
mortality of patients with normal protein C levels at base-
line (26.0%) increased if there was a decrease in their pro-
tein C levels ≥ 10% (36.7%) and decreased if there was no
drop in their protein C levels ≥ 10% (20.6%).
Day 1 improvement of protein C levels: effect of DrotAA
Although randomization in the PROWESS trial created a
placebo group with slightly higher median baseline protein
C levels (P = 0.06, Table 3), by day 1, DrotAA-treated
patients had significantly increased protein C levels (P =
0.008). The median day 1 change in protein C showed a
6% increase for DrotAA-treated patients, compared with a
0% change for placebo (P < 0.0001).
Table 4 demonstrates the specificity of the DrotAA
effect. There was no significant difference between treat-
ment groups in day 1 levels or the day 1 change in two
other markers of coagulation, protein S (P = 0.41 and P =
0.59, respectively) and antithrombin III (P = 0.61 and P =
0.88, respectively). Although there was no significant dif-
ference between treatment groups in the day 1 levels of
the inflammation marker IL-6 (P = 0.44), the day 1 change
in IL-6 was significantly reduced in the DrotAA group
(P = 0.006). There was a slight imbalance of higher IL-6
levels in the DrotAA group at baseline (P = 0.08).
The proportion of PROWESS patients in each baseline
protein C category that improved or worsened by day 1
with DrotAA treatment is illustrated in the bottom half
of Table 3. DrotAA significantly increased the propor-
tion of severely deficient patients whose protein C levels
improved to deficient or normal levels (that is to say
>40% activity, P < 0.0001). In addition, DrotAA signifi-
cantly decreased the proportion of deficient patients
who had a ≥ 10% drop in protein C (P = 0.0002) and
numerically reduced the proportion of normal patients
who had a ≥ 10% drop in protein C (P = 0.09).
Survival curves (Kaplan-Meier estimates) of PRO-
WESS placebo and DrotAA-treated patients, based on
baseline protein C class and the day 1 change in protein
C levels, are presented in Figure 2. Curves of placebo
patients (Figure 2a) who were severely deficient (≤ 40%)
and deficient (41–80%) at baseline were significantly
better in patients whose day 1 protein C levels improved
to >40% or stabilized (no decrease ≥ 10%) than those
whose day 1 protein C values remained ≤ 40% or had a
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≥ 10% decrease. In the relatively small subgroup of
patients with normal (>80%) baseline protein C, the
same trend was observed. In general, this same pattern
was observed in DrotAA-treated patients (Figure 2b),
although the degree of increase in mortality of patients
with normal (>80%) baseline protein C and a ≥ 10%
decrease was not observed.
Discussion
This analysis demonstrates that the directional change
of protein C levels correlates with outcome and the
change from baseline in the first day provides more
information on the eventual prognosis than do baseline
protein C levels alone in individuals with severe sepsis.
Additionally, the risk for death associated with various
protein C levels seems to follow a threshold effect with
clear risk classes. Furthermore, early changes in protein
C levels, in combination with baseline protein C levels,
predict outcome. Patients whose protein C levels fail to
stabilize (deficient patients and normal patients) or fail
to improve (severely deficient patients) faced a higher
risk of death. Finally, DrotAA appears to alter survival
Figure 1 PROWESS 28-day placebo mortality rates: effect of baseline protein C class. Placebo patient baseline and day 1 protein C levels were assessed
and patient outcomes at 28 days determined. Twenty eight-day mortalities, based on baseline protein C and day 1 protein C levels are presented.
Mortality of severely deficient patients at baseline increased if protein C levels remained ≤ 40% and decreased if protein C levels increased to >40%.
Mortality of deficient (41–80%) and normal (>80%) patients increased if there was a ≥ 10% drop in protein C levels and decreased if there was no drop
≥ 10%. The area/% above the dashed lines in all baseline bar graphs represent patients that died before a day 1 protein C measurement was performed.
Table 3 Baseline and Day 1 protein C activity: effect of drotrecogin alfa (activated) (DrotAA) and proportion of
patients that improved or worsened by baseline protein C class
Parameter Treatment group
Placebo (n = 709) DrotAA (n = 743) P value
Protein C activitya
Baseline 50% (34, 68) 47% (31, 64) 0.06
Day 1 47% (30, 72) 52% (36, 72) 0.008
Day 1 change 0% (-10, 9) 6% (-4, 16) <0.0001
Proportion of patients improved or worsened (% of patients)b
Baseline protein C ≤ 40% and day 1 protein C >40% 19.4 35.5 <0.0001
Baseline protein C 40–80% and day 1 protein C decreased ≥ 10% 29.6 17.6 0.0002
Baseline protein C >80% and day 1 protein C decreased ≥ 10% 30.6 19.8 0.09
aSummary statistics reported as the median (25th percentile, 75th percentile), and P values from Wilcoxon rank-sum tests (P < 0.05 significant).
bImproved, baseline protein C ≤ 40% and day 1 protein C >40%; Worsened, baseline protein C 41–80% or >80% and a day 1 decrease in protein C ≥ 10%.
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Table 4 Baseline and day 1 values for protein S, antithrombin III, and IL-6 by treatment group in the PROWESS trial
Parameter Treatment group
Placebo (n = 709) Drotrecogin alfa (activated) (n = 743) P value
Protein S activity
Baseline 39% (24, 59) 35% (22, 57) 0.09
Day 1 36% (23, 57) 35% (22, 56) 0.41
Day 1 change 0% (-9, 7) 0% (-10, 9) 0.59
Antithrombin III
Baseline 60% (45, 75) 59% (44, 75) 0.50
Day 1 59% (45, 75) 59% (44, 76) 0.61
Day 1 change 0% (-10, 9) 0% (-8, 7) 0.88
IL-6
Baseline 436 (126, 2338) 523 (156, 2701) 0.08
Day 1 199 (68, 717) 211 (77, 685) 0.44
Day 1 change -157 (-1073, -6) -225 (-1922, -27) 0.006
Summary statistics reported as the median (25th percentile, 75th percentile), and P values from Wilcoxon rank-sum tests (P < 0.05 significant).
Figure 2 PROWESS 28-day survival curves based on baseline and day 1 protein C activity levels. Baseline and day 1 protein C levels for patients by
treatment group were assessed and 28-day outcomes determined. Kaplan-Meier survival curves of each group are presented. Curves were
compared using the log-rank test and P < 0.05 was considered significant. Severely deficient (≤ 40%), moderately deficient (41–80%) and normal
(>80%) baseline protein C categories are presented from left to right. (a) Survival curves of placebo patients. In all cases, if day 1 protein C levels
improved (to >40%) or remained stable (no ≥ 10% decrease), survival was higher than if protein C levels remained ≤ 40% or decreased by ≥ 10%.
The improvement was significant only for severely deficient and deficient patients.(b) Survival curves of PROWESS drotrecogin alfa (activated)
(DrotAA) patients. A similar pattern was observed in DrotAA-treated patients as in placebo patients. In all cases, 28-day survival was higher if day 1
protein C levels improved (to >40%) or remained stable than if they remained ≤ 40% or decreased by ≥ 10%. The improvement was significant
only for severely deficient and deficient patients.
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through its direct impact on endogenous protein C
levels.
The current study differs from and builds on a previous
study investigating the interaction of protein C levels and
DrotAA treatment [15]. For that past assessment, all pro-
tein-C-deficient patients were pooled into a common
group and no effort was made to separate the moderately
and severely deficient protein C classes. In the present
analysis, risk for mortality was not continuous within the
deficient group. The likelihood of death was very high in
severely deficient protein C patients (protein C levels ≤
40% of normal), while the risk of death in patients with
deficient (41–80% of normal) and normal (>80% of nor-
mal) protein C levels was equivalent. It is possible, how-
ever, that the risk of death in moderately deficient and
normal protein C groups would not be the same if protein
C was analyzed over a greater period of time.
Our observation that mortality increased if baseline
protein C levels were >40% and if a patient’s day 1 pro-
tein C levels fell by ≥ 10% is novel. These results are con-
sistent with previous studies that suggested decreases in
protein C levels precede overt clinical symptoms [7-9]
and may be predictive of increased mortality [7-11].
Hence, future investigations should focus on measuring
protein C levels as soon as possible after sepsis is sus-
pected and then evaluate the role for serial protein C
measurements. This could potentially provide a more
rapid and accurate assessment of the patient’s status. If
such studies confirm that specific rapid declines in pro-
tein C levels can be readily detected, and further that
they precede clinical deterioration, this information
could be used to guide therapy.
Results from this study also suggested that improve-
ments in outcome hinge on increases in protein C levels
over the first day following diagnosis and baseline protein
C measurement. These improvements were observed to
occur in patients not treated with DrotAA and could be a
component of the natural host response or a result of the
numerous currently available clinical interventions such
as infection source control, antibiotics or other measures.
On the other hand, the results presented here provide
supportive evidence that DrotAA treatment specifically
increases endogenous protein C levels.
Regardless of the reason for improvement, the change
from baseline data to day 1 data emphasized that it is
important for these changes to occur rapidly. If protein C
levels decrease by as little as 10% on day 1, mortality
increases significantly among most individuals. Moreover,
DrotAA treatment significantly reduces mortality in the
severely deficient protein C group, probably reflecting
these patients being more likely to have increased protein
C levels at day 1 because of treatment with DrotAA. Con-
versely, DrotAA-treated patients with moderately deficient
(41–80% of normal) or normal (80% of normal) protein C
levels at baseline were less likely to have a ≥ 10% drop in
protein C levels. This fact probably explains that the treat-
ment effect of DrotAA is less robust in these populations.
In lower risk patients DrotAA prevented the progression
of low-risk individuals to high-risk status, presumably by
stabilizing protein C levels. This apparent association
between DrotAA treatment, increased protein C levels,
and improved survival may suggest that the mechanism of
action for DrotAA is primarily reflective of its direct
impact on protein C levels.
The relationship between protein C and DrotAA
appears unique. For example, the increase in protein C
levels with DrotAA treatment was not observed in a differ-
ent anticoagulant (antithrombin III), although derange-
ments in other coagulation markers have been previously
observed to improve with DrotAA treatment [13,14]. The
significant reduction from baseline levels of IL-6 could be
from the anti-inflammatory activity of protein C, which
stems from its antithrombotic activity or from a yet to be
described mechanism. The potential insight gained by
incorporation of dynamic assessments of protein C rein-
forces the plausibility of why DrotAA is efficacious in
severe sepsis. Additional prospective studies looking at
more rapid diagnosis of sepsis, early and serial assessment
of individual changes in protein C levels, titration of
DrotAA dose, and duration of DrotAA treatment using
serial protein C assessment are clearly needed to further
clarify the results presented here.
There are important limitations to the present study. As
a result of the exclusion criteria (patients at high risk of
bleeding, patients with low platelet count, and so on), the
actual prevalence of patients with low protein C levels in
severe sepsis may be higher than observed in this study.
Likewise, although many of the parameters assessed in this
study were prospectively defined, most of the analyses in
this study were performed in a retrospective manner.
Finally, limitations in the availability of samples (patients
with missing baseline protein C values) prevented a more
robust analysis of the early daily changes in protein C.
Conclusion
In summary, the current study confirmed that baseline
protein C levels are an independent predictor of outcome
in severe sepsis patients. Early changes in protein C levels
(such as day 1) were also significant risk factors in combi-
nation with baseline protein C levels. The risk associated
with protein C levels appears to be categorical rather
than continuous in nature. The data imply that DrotAA
treatment decreases mortality in two ways: by raising
protein C levels above 40% of the normal threshold, and
by reducing the number of moderately deficient patients
and normal patients who had a decrease in their baseline
protein C levels ≥ 10%. Finally, an association between
DrotAA treatment, increased protein C levels, and
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improved survival exists that suggests a mechanism of
action.
Key messages
• A decline in protein C levels in patients with severe
sepsis and septic shock identifies a population at high
risk for death.
• Dynamic, temporal analysis of changes in protein C
levels provides more insight into probable outcomes
than a static, one-time assessment.
• The risk for death associated with various protein C
levels seems to follow a threshold effect with clear risk
classes.
• Drotrecogin alfa (activated) appears to exert its effect
on mortality reduction in part through increasing levels
of protein C.
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